POSTN and asthma: Regarding previous studies, lebrikizumab treatment could effectively curb exacerbation of asthma especially in patients with high serum POSTN levels, which suggests us that we need further studies to investigate whether lebrikizumab could treat ECRS patients and how outcomes differentiate among various subgroups.